Pharvaris N.V. (PHVS) stock
PHVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$33.83−0.35 (-1.02%)
Close on Nov 12, 2026Market cap $2.21BP/E –Yield –
Pharvaris r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was €124.48M, up 26.3% from the year before. The highest annual figure on record is €124.48M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €124.48M | +26.3% |
| FY2024 | Dec 31, 2024 | €98.56M | +50.3% |
| FY2023 | Dec 31, 2023 | €65.58M | +14.3% |
| FY2022 | Dec 31, 2022 | €57.38M | +60.3% |
| FY2021 | Dec 31, 2021 | €35.79M | +83.5% |
| FY2020 | Dec 31, 2020 | €19.51M | +243.2% |
| FY2019 | Dec 31, 2019 | €5.68M | +55.9% |
| FY2018 | Dec 31, 2018 | €3.65M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | €35.00M | +155.1% |
| Q2 FY2025 | Jun 30, 2025 | €29.61M | +267.3% |
| Q2 FY2024 | Jun 30, 2024 | €23.07M | – |
| Q2 FY2023 | Jun 30, 2023 | €14.68M | – |
| Q2 FY2022 | Jun 30, 2022 | €13.72M | – |
| Q2 FY2021 | Jun 30, 2021 | €8.06M | – |
See a number that looks wrong?